{"id":727582,"date":"2023-02-01T07:37:55","date_gmt":"2023-02-01T12:37:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/"},"modified":"2023-02-01T07:37:55","modified_gmt":"2023-02-01T12:37:55","slug":"enveric-biosciences-to-present-at-the-bio-ceo-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/","title":{"rendered":"Enveric Biosciences to Present at the BIO CEO & Investor Conference"},"content":{"rendered":"

<\/p>\n

Enveric Biosciences to Present at the BIO CEO & Investor Conference<\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nEnveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.\n<\/p>\n

\nDetails of the presentation are as follows:\n<\/p>\n\n\n\n\n\n
\n

Event:<\/b><\/p>\n<\/td>\n

\n

\nBIO CEO & Investor Conference\n<\/p>\n<\/td>\n<\/tr>\n

\n

Date:<\/b><\/p>\n<\/td>\n

\n

\nMonday, February 6, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

Time:<\/b><\/p>\n<\/td>\n

\n

\n3:00 p.m., EST\n<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/b><\/p>\n<\/td>\n

\n

\nWinter Garden Room, Marriott Marquis, New York City\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nDuring the conference, members of Enveric\u2019s management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, showcasing the company\u2019s business and clinical development strategy, recent corporate achievements, and anticipated milestones.\n<\/p>\n

About Enveric Biosciences<\/b><\/p>\n

\nEnveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Leveraging its unique discovery and development platform, The Psybrary\u2122, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications. Enveric\u2019s lead program, the EVM201 Series, comprises next generation synthetic psilocybin analogues that are considered prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series \u2013 EB-373 \u2013 for the treatment of anxiety disorders. Enveric is also advancing its third generation of therapeutics, the EVM301 Series, to offer a holistic approach for treating central nervous system disorders. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as \u201cplans,\u201d\u201d expects\u201d or \u201cdoes not expect,\u201d \u201cproposed,\u201d \u201cis expected,\u201d \u201cbudgets,\u201d \u201cscheduled,\u201d \u201cestimates,\u201d \u201cforecasts,\u201d \u201cintends,\u201d \u201canticipates\u201d or \u201cdoes not anticipate,\u201d or \u201cbelieves,\u201d or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to successfully spin-off its cannabinoid assets; the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric\u2019s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric\u2019s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric\u2019s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric\u2019s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric\u2019s filings with the Securities and Exchange Commission (SEC), including Enveric\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230131006074\/en\/<\/a><\/span><\/p>\n

Investor Relations
\n<\/b>
Tiberend Strategic Advisors, Inc.
\n
Daniel Kontoh-Boateng
\n
(862) 213-1398
\n
dboateng@tiberend.com<\/a><\/p>\n

Media Relations
\n<\/b>
Tiberend Strategic Advisors, Inc.
\n
Casey McDonald
\n
(646) 577-8520
\n
cmcdonald@tiberend.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Canada Florida Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Health Mental Health Other Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Enveric Biosciences to Present at the BIO CEO & Investor Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as follows: Event: BIO CEO & Investor Conference Date: Monday, February 6, 2023 Time: 3:00 p.m., EST Location: Winter Garden Room, Marriott Marquis, New York City During the conference, members of Enveric\u2019s management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, … <\/p>\n

Continue reading “Enveric Biosciences to Present at the BIO CEO & Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-727582","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnveric Biosciences to Present at the BIO CEO & Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enveric Biosciences to Present at the BIO CEO & Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enveric Biosciences to Present at the BIO CEO & Investor Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as follows: Event: BIO CEO & Investor Conference Date: Monday, February 6, 2023 Time: 3:00 p.m., EST Location: Winter Garden Room, Marriott Marquis, New York City During the conference, members of Enveric\u2019s management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, … Continue reading "Enveric Biosciences to Present at the BIO CEO & Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T12:37:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enveric Biosciences to Present at the BIO CEO & Investor Conference\",\"datePublished\":\"2023-02-01T12:37:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/\"},\"wordCount\":766,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/\",\"name\":\"Enveric Biosciences to Present at the BIO CEO & Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-02-01T12:37:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enveric Biosciences to Present at the BIO CEO & Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enveric Biosciences to Present at the BIO CEO & Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Enveric Biosciences to Present at the BIO CEO & Investor Conference - Market Newsdesk","og_description":"Enveric Biosciences to Present at the BIO CEO & Investor Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Enveric Biosciences (NASDAQ: ENVB) (\u201cEnveric\u201d or the \u201cCompany\u201d), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as follows: Event: BIO CEO & Investor Conference Date: Monday, February 6, 2023 Time: 3:00 p.m., EST Location: Winter Garden Room, Marriott Marquis, New York City During the conference, members of Enveric\u2019s management team will conduct one-on-one meetings with registered investors and pharmaceutical companies, … Continue reading \"Enveric Biosciences to Present at the BIO CEO & Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-01T12:37:55+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enveric Biosciences to Present at the BIO CEO & Investor Conference","datePublished":"2023-02-01T12:37:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/"},"wordCount":766,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/","name":"Enveric Biosciences to Present at the BIO CEO & Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-02-01T12:37:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230131006074r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enveric-biosciences-to-present-at-the-bio-ceo-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enveric Biosciences to Present at the BIO CEO & Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=727582"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727582\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=727582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=727582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=727582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}